Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

Abstract Background Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. Case presentation We present a patient with refractory OCCC in whom conventional chemo...

Full description

Bibliographic Details
Main Authors: Yu-Chien Lin, Kuo-Chang Wen, Pi-Lin Sung, Yu-Ting Chou, Phui-Ly Liew, Lin-Yu Chen, Rui-Lan Huang, Hung-Cheng Lai, Lu-Te Chang
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Journal of Ovarian Research
Subjects:
Angiogenesis inhibitor
ARID1A
Checkpoint inhibitor
Ovarian clear cell carcinoma
Online Access:https://doi.org/10.1186/s13048-020-00751-3

Internet

https://doi.org/10.1186/s13048-020-00751-3

Similar Items